Fish oil administration in older adults: is there potential for adverse events? A systematic review of the literature

BMC Geriatrics

Michelle D Miller²  Lynne Cobiac²  Robert J Fraser¹  Michael J James³  Leslie G Cleland³  Maria Crotty⁴  Anthony M Villani² 

[1] Flinders Clinical Effectiveness, School of Medicine, Flinders University, Adelaide, South Australia;Department of Nutrition and Dietetics, School of Medicine, Flinders University, Adelaide, South Australia;Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia;Department of Rehabilitation and Aged Care, School of Medicine, Flinders University, Adelaide, South Australia

关键词: Older adults;    Adverse events;    Docosahexaenoic acid;    Eicosapentaenoic acid;    Fish oil;   

Others  :  857727
DOI  :  10.1186/1471-2318-13-41

 received in 2012-11-02, accepted in 2013-04-29,  发布年份 2013

【 摘 要 】

Background

Omega-3 (n-3) fatty acid supplementation is becoming increasingly popular. However given its antithrombotic properties the potential for severe adverse events (SAE) such as bleeding has safety implications, particularly in an older adult population. A systematic review of randomized control trials (RCT) was conducted to explore the potential for SAE and non-severe adverse events (non-SAE) associated with n-3 supplementation in older adults.

Methods

A comprehensive search strategy using Medline and a variety of other electronic sources was conducted. Studies investigating the oral administration of n-3 fish oil containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or both against a placebo were sourced. The primary outcome of interest included reported SAE associated with n-3 supplementation. Chi-square analyses were conducted on the pooled aggregate of AEs.

Results

Of the 398 citations initially retrieved, a total of 10 studies involving 994 older adults aged ≥60 years were included in the review. Daily fish oil doses ranged from 0.03 g to 1.86 g EPA and/or DHA with study durations ranging from 6 to 52 weeks. No SAE were reported and there were no significant differences in the total AE rate between groups (n-3 intervention group: 53/540; 9.8%; placebo group: 28/454; 6.2%; p = 0.07). Non-SAE relating to gastrointestinal (GI) disturbances were the most commonly reported however there was no significant increase in the proportion of GI disturbances reported in participants randomized to the n-3 intervention (n-3 intervention group: 42/540 (7.8%); placebo group: 24/454 (5.3%); p = 0.18).

Conclusions

The potential for AEs appear mild-moderate at worst and are unlikely to be of clinical significance. The use of n-3 fatty acids and the potential for SAE should however be further researched to investigate whether this evidence is consistent at higher doses and in other populations. These results also highlight that well-documented data outlining the potential for SAE following n-3 supplementation are limited nor adequately reported to draw definitive conclusions concerning the safety associated with n-3 supplementation. A more rigorous and systematic approach for monitoring and recording AE data in clinical settings that involve n-3 supplementation is required.

【 授权许可】

   
2013 Villani et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Calder PC: Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie 2009, 91:791-795.
• [2]Goldberg RJ, Katz J: A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 2007, 129:210-223.
• [3]Turner D, Zlotkin S, Shah P, Griffiths A: Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease (Review). Cochrane Database Syst Rev 2007, 2:1-18.
• [4]Teitelbaum JE, Allan Walker W: Review: the role of omega 3 fatty acids in intestinal inflammation. J Nutr Biochem 2001, 12:21-32.
• [5]MacLean CH, Mojica WA, Newberry SJ, Pencharz J, Garland RH, Tu W, Hilton LG, Gralnek IM, Rhodes S, Khanna P: Systematic review of the effects of n–3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 2005, 82:611-619.
• [6]Nettleton JA, Katz R: n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review. JADA 2005, 105:428-440.
• [7]Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Capps NE, Smith GD, Riemersma RA, Ebrahim S: Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ 2001, 322:757-763.
• [8]Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J: n–3 fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006, 84:5-17.
• [9]Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JPT, Capps NE: Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006, 332:752-760.
• [10]Dewey A, Baughan C, Dean T, Higgins B, Johnson I: Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007, 1:1-27.
• [11]Kris-Etherton PM, Grieger JA, Etherton TD: Dietary reference intakes for DHA and EPA. Prost Leuk Ess Fatty Acids 2009, 81:99-104.
• [12]Australia and New Zealand National Health and Medical Research Council: Nutrient reference values for Australia and New Zealand including recommended dietary intakes. Australian Government: Department of Health and Ageing Reference no: N35, N36, N37, N38, N264, N265; 2006.
• [13]National Heart Foundation of Australia: Review of the evidence: Fish, fish oils, n-3 polyunsaturated fatty acids and cardiovascular health. 2008, 1-7.
• [14]Armstrong AR, Thiébaut SP, Brown LJ, Nepal B: Australian adults use complementary and alternative medicine in the treatment of chronic illness: a national study. Aust New Zeal J Public Health 2011, 35:384-390.
• [15]Goh L, Vitry A, Semple S, Esterman A, Luszcz M: Self-medication with over-the-counter drugs and complementary medications in South Australia’s elderly population. BMC Complem Altern Med 2009, 9:1-10. BioMed Central Full Text
• [16]Yashodhara BM, Umakanth S, Pappachan JM, Bhat SK, Kamath R, Choo BH: Omega-3 fatty acids: a comprehensive review of their role in health and disease. Postgrad Med J 2009, 85:84-90.
• [17]Ruxton CHS, Reed SC, Simpson MJA, Millington KJ: The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Dietet 2004, 17:449-459.
• [18]Calder P: Polyunsaturated fatty acids, inflammation, and immunity. Lipids 2001, 36:1007-1024.
• [19]Calder P: Dietary fatty acids and the immune system. Lipids 1999, 34:S137-S140.
• [20]Calder PC: n–3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006, 83:S1505-1519S.
• [21]Saravanan P, Davidson NC, Schmidt EB, Calder PC: Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010, 376:540-550.
• [22]Knapp HR, Reilly IAG, Alessandrini P, FitzGerald GA: In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. New Eng J Med 1986, 314:937-942.
• [23]Kristensen S, Bach Iversen A, Schmidt E: n - 3 polyunsaturated fatty acids and coronary thrombosis. Lipids 2001, 36:S79-S82.
• [24]Bays HE: Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007, 99:S35-S43.
• [25]McClaskey E, Michalets E: Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. J Human Pharmacol Drug Therapy 2007, 27:152-160.
• [26]Buckley MS, Goff AD, Knapp WE: Fish oil interaction with warfarin. Ann Pharmacother 2004, 38:50-53.
• [27]Turner M: Safety of fish oil and omega-3 fatty acids. Medicines Safety Update 2010, 2:48-52.
• [28]Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996, 17:1-12.
• [29]Bechoua S, Dubois M, Vericel E, Chapuy P, Lagarde M, Prigent A: Influence of very low dietary intake of marine oil on some functional aspects of immune cells in healthy elderly people. BJN 2003, 89:523-531.
• [30]Véricel E, Calzada C, Chapuy P, Lagarde M: The influence of low intake of n-3 fatty acids on platelets in elderly people. Atherosclerosis 1999, 147:187-192.
• [31]Thies F, Nebe-von-Caron G, Powell JR, Yaqoob P, Newsholme EA, Calder PC: Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y. Am J Clin Nutr 2001, 73:539-548.
• [32]Thies F, Nebe-von-Caron G, Powell JR, Yaqoob P, Newsholme EA, Calder PC: Dietary supplementation with gamma-linolenic acid or fish oil decreases T lymphocyte proliferation in healthy older humans. J Nutr 2001, 131:1918-1927.
• [33]Vedin I, Cederholm T, Freund-Levi Y, Basun H, Hjorth E, Irving GF, Eriksdotter-Jonhagen M, Schultzberg M, Wahlund L-O, Palmblad J: Reduced prostaglandin F2α release from blood mononuclear leukocytes after oral supplementation of n-3 fatty acids: the OmegAD study. J Lipid Research 2010, 51:1179-1185.
• [34]Vedin I, Cederholm T, Freund Levi Y, Basun H, Garlind A, Faxen-Irving G, Eriksdotter-Jonhagen M, Vessby B, Wahlund L-O, Palmblad J: Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr 2008, 87:1616-1622.
• [35]Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund L-O, Palmblad J: Omega-3 fatty acid treatment in 174 patients with mild to moderate alzheimer disease: omegAD study: a randomized double-blind trial. Arch Neurol 2006, 63:1402-1408.
• [36]van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, OldeRikkert MGM, Beekman ATF, de Groot CPGM: Effect of fish oil supplementation on quality of life in a general population of older Dutch subjects: a Randomized, Double-blind, PLacebo-Controlled Trial. J Am Geriatr Soc 2009, 57:1481-1486.
• [37]van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Dullemeijer C, OldeRikkert MGM, Beekman ATF, de Groot LC: Effect of fish oil on cognitive performance in older subjects. Neurology 2008, 71:430-438.
• [38]van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Hoefnagels WH, Beekman AT, de Groot LC: Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2008, 88:706-713.
• [39]Bouwens M, van de Rest O, Dellschaft N, Bromhaar MG, de Groot LC, Geleijnse JM, Müller M, Afman LA: Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr 2009, 90:415-424.
• [40]Rondanelli M, Giacosa A, Opizzi A, Pelucchi C, La Vecchia C, Montorfano G, Negroni M, Berra B, Politi P, Rizzo AM: Effect of omega-3 fatty acid supplementation on depressive symptoms and on health-related quality of Life in the treatment of elderly women with depression: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr 2010, 29:55-64.
• [41]Querques G, Benlian P, Chanu B, Portal C, Coscas G, Soubrane G, Souied E: Nutritional AMD treatment phase I (NAT-1): feasibility of oral DHA supplementation in age-related macular degeneration. Euro J Ophthalmology 2009, 19:100-106.
• [42]Gruenwald J, Petzold E, Busch R, Petzold HP, Graubaum H-J: Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis. Adv Ther 2009, 26:858-871.
• [43]Fakhrzadeh H, Ghaderpanahi M, Sharifi F, Mirarefin M, Badamchizade Z, Akbari Kamrani A, Larijani B: The effects of low dose n-3 fatty acids on serum lipid profiles and Insulin resistance of the elderly: a Randomized Controlled Clinical Trial. Int J Vitam Nutr Res 2010, 80:107-116.
• [44]Holguin F, Téllez-Rojo MM, Lazo M, Mannino D, Schwartz J, Hernández M, Romieu I: Cardiac autonomic changes associated with fish oil vs soy oil supplementation in the elderly. Chest 2005, 127:1102-1107.
• [45]Smith GI, Atherton P, Reeds DN, Mohammed BS, Rankin D, Rennie MJ, Mittendorfer B: Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr 2011, 93:402-412.
• [46]Thies F, Miles E, Nebe-von-Caron G, Powell J, Hurst T, Newsholme E, Calder P: Influence of dietary supplementation with long-chain n - 3 or n - 6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. Lipids 2001, 36:1183-1193.
• [47]Harris WS: Expert Opinion: Omega-3 fatty acids and bleeding—cause for concern? Am J Cardiol 2007, 99:S44-S46.
• [48]Watson PD, Joy PS, Nkonde C, Hessen SE, Karalis DG: Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel—versus—aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol 2009, 104:1052-1054.
• [49]Eslick GD, Howe P, Smith C, Priest R, Bensoussan A: Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009, 136:4-16.
• [50]Riediger ND, Othman RA, Suh M, Moghadasian MH: A systemic review of the roles of n-3 fatty acids in health and disease. JADA 2009, 109:668-679.
• [51]Finnegan YE, Minihane AM, Leigh-Firbank EC, Kew S, Meijer GW, Muggli R, Calder PC, Williams CM: Plant and marine derived n - 3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects. Am J Clin Nutr 2003, 77:783-795.
• [52]Pedersen H, Petersen M, Major-Pedersen A, Jensen T, Nielsen NS, Lauridsen S, Marckmann P: Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes. Eur J Clin Nutr 2003, 57:713-720.
• [53]Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health. JAMA 2006, 296:1885-1899.
• [54]Cleland L, James M, Proudman S: Fish oil: what the prescriber needs to know. Arthritis Res Ther 2006, 8:1-9.
• [55]Dangour AD, Andreeva VA, Sydenham E, Uauy R: Omega 3 fatty acids and cognitive health in older people. Br J Nutr 2012, 107(S2):S152-S158.
• [56]Lambert EV, Goedecke JH, Bluett K, Heggie K, Claassen A, Rae DE, West S, Dugas J, Dugas L, Meltzer S: Conjugated linoleic acid versus high-oleic acid sunflower oil: effects on energy metabolism, glucose tolerance, blood lipids, appetite and body composition in regularly exercising individuals. BJN 2007, 97:1001-1011.
• [57]Brouwer IA, Zock PL, Camm AJ, Böcker D, Hauer RN, Wever EF, Dullemeijer C, Ronden JE, Katan MB, Lubinski A: Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators. JAMA 2006, 295:2613-2619.
• [58]Yaxley A, Miller MD, Fraser RJ, Cobiac L, Crotty M: Testing the acceptability of liquid fish oil in older adults. Asia Pac J Clin Nutr 2011, 20:175-179.